Thus, we adopted a treatment strategy that included rapamycin with IL-2/IL-2mAb complexes to enhance Treg cell function in vivo for targeting T-cell-mediated immune responses and induction of FVIII-specific tolerance in hemophilia A mice with pre-existing antibodies. This evidence concerns the gene IL2 and hemophilia A.